 |
 |
Clinical Trials
Interesting Articles
- A Screen for Suppressors of Gross Chromosomal Rearrangements Identifies a Conserved Role for PLP in Preventing DNA Lesions
- Producing primate embryonic stem cells by somatic cell nuclear transfer
- Origins of breast cancer subtypes and therapeutic implications
- Identifiability in Genomic Research
Commentaries
- "Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells"
- "Resistance to therapy caused by intragenic deletion in BRCA2"
"Secondary mutations as a mechanism ofs cisplatin resistance in BRCA2-mutated cancers" - "Endogenous human microRNAs that suppress breast cancer metastasis"
"The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis"
Clinical Trials
Randomized Trial of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclosphamide (FEC)
| Study Duration: | Nov. 2005 - Dec. 2014 |
| Principal Investigators: | Prof. Masakazu Toi (President of OOTR, Kyoto University), Dr. Shiniji ohno (Director of OOTR, Kyusyu Cancer Center), Dr. Louis W.C. Chow (Executive Director of OOTR) |
| Participating Institutes: | 16 (as of 30th April, 2009) |
| Target: | 500 cases |
| Registration: | Closed |
| e-mail: | info@ootr.org(English) info@ootr-institute.org(Japanese and English) |
